Deutsche Boerse chief executive Carsten Kengeter said he was sure that allegations of insider trading against him would prove unfounded, speaking in Frankfurt on Thursday.
The Frankfurt public prosecutor is investigating Kengeter over a multi-million-euro share purchase in December 2015, some two months before Deutsche Boerse announced that it was in merger talks with the the London Stock Exchange (LSE). As a result, the share prices of both exchange operators rose markedly.
Kengeter avoided questions about the possibility of his resignation at Thursday‘s presentation of Deutsche Boerse‘s annual results.
Deutsche Boerse‘s finance executive Gregor Pottmeyer said the planned merger with LSE racked up costs of 66 million euros (70 million dollars) last year for the exchange operator.
A successful conclusion to the deal is expected to cost a total of 150 million euros, he said, in particular due to the performance-related fees of the participating banks.
Last year, the British referendum decision to leave the EU raised questions about plans to base the merged exchange operator in London.
The merger still needs approval from the European Commission and the exchange supervisory authority of the German state of Hesse.
Full Content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas